The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation
Abstract
:1. Introduction
2. Materials and Methods
2.1. Cells and Reagents
2.2. Plasmid Constructs and Transfection
2.3. Immunoblotting
2.4. Coimmunoprecipitation (Co-IP)
2.5. Confocal Microscope
2.6. SUMOylation and Ubiquitination Assay
2.7. Statistical Analyses
3. Results
3.1. N Protein Interacts with Human SUMO-Conjugating E2 Enzyme UBC9
3.2. SARS-COV-2 N Protein Enhances Molecular Interaction between UBC9 and MAVS
3.3. The Interaction between MAVS and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation
3.4. The Interaction of N Protein and UBC9 Plays a Crucial Role in Regulating the SUMOylation and Ubiquitination Modifications of MAVS
3.5. UBC9 Plays a Critical Role in the Process of Impaired IFN I Response Caused by the Interaction between the N Protein and MAVS during Virus Infection
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kato, H.; Takeuchi, O.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Matsui, K.; Uematsu, S.; Jung, A.; Kawai, T.; Ishii, K.J.; et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441, 101–105. [Google Scholar] [CrossRef] [PubMed]
- Rehwinkel, J.; Gack, M.U. RIG-I-like receptors: Their regulation and roles in RNA sensing. Nat. Rev. Immunol. 2020, 20, 537–551. [Google Scholar] [CrossRef]
- Pichlmair, A.; Schulz, O.; Tan, C.P.; Näslund, T.I.; Liljeström, P.; Weber, F.; Reis e Sousa, C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 2006, 314, 997–1001. [Google Scholar] [CrossRef]
- Hadjadj, J.; Yatim, N.; Barnabei, L.; Corneau, A.; Boussier, J.; Smith, N.; Péré, H.; Charbit, B.; Bondet, V.; Chenevier-Gobeaux, C.; et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020, 369, 718–724. [Google Scholar] [CrossRef] [PubMed]
- Shemesh, M.; Aktepe, T.E.; Deerain, J.M.; McAuley, J.L.; Audsley, M.D.; David, C.T.; Purcell, D.F.J.; Urin, V.; Hartmann, R.; Moseley, G.W.; et al. SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoS Pathog. 2021, 17, e1009800. [Google Scholar]
- Xiangbo, Z.; Zhaofang, Y.; Jinjing, G.; Zhuandi, G.; Suocheng, W. Bovine coronavirus nucleocapsid suppresses IFN-beta production by inhibiting RIG-I-like receptors pathway in host cells. Arch. Microbiol. 2022, 204, 536. [Google Scholar] [CrossRef] [PubMed]
- Yelemali, P.; Hao, L.; Liu, Q. Mechanisms of host type I interferon response modulation by the nucleocapsid proteins of alpha- and betacoronaviruses. Arch. Virol. 2022, 167, 1925–1930. [Google Scholar] [CrossRef]
- Chen, K.; Xiao, F.; Hu, D.; Ge, W.; Tian, M.; Wang, W.; Pan, P.; Wu, K.; Wu, J. SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-beta Production. Viruses 2020, 13, 47. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Dai, T.; Qin, Z.; Pan, T.; Chu, F.; Lou, L.; Zhang, L.; Yang, B.; Huang, H.; Lu, H.; et al. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat. Cell Biol. 2021, 23, 718–732. [Google Scholar] [CrossRef] [PubMed]
- Fan, Z.; Zhuo, Y.; Tan, X.; Zhou, Z.; Yuan, J.; Qiang, B.; Yan, J.; Peng, X.; Gao, G.F. SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. J. Med. Virol. 2006, 78, 1365–1373. [Google Scholar] [CrossRef]
- Matsuo, T. Viewing SARS-CoV-2 Nucleocapsid Protein in Terms of Molecular Flexibility. Biology 2021, 10, 454. [Google Scholar] [CrossRef] [PubMed]
- Fan, Y.; Li, X.; Zhang, L.; Zong, Z.; Wang, F.; Huang, J.; Zeng, L.; Zhang, C.; Yan, H.; Zhang, L.; et al. SUMOylation in Viral Replication and Antiviral Defense. Adv. Sci. 2022, 9, e2104126. [Google Scholar] [CrossRef]
- Choi, G.W.; Lee, Y.; Yun, M.; Kang, J.; Lee, S.B. Formation of SUMO3-conjugated chains of MAVS induced by poly(dA:dT), a ligand of RIG-I, enhances the aggregation of MAVS that drives the secretion of interferon-beta in human keratinocytes. Biochem. Biophys. Res. Commun. 2020, 522, 939–944. [Google Scholar] [CrossRef] [PubMed]
- Hou, F.; Sun, L.; Zheng, H.; Skaug, B.; Jiang, Q.X.; Chen, Z.J. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell 2011, 146, 448–461. [Google Scholar] [CrossRef]
- Liu, B.; Zhang, M.; Chu, H.; Zhang, H.; Wu, H.; Song, G.; Wang, P.; Zhao, K.; Hou, J.; Wang, X.; et al. The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination. Nat. Immunol. 2017, 18, 214–224. [Google Scholar] [CrossRef]
- Dai, T.; Zhang, L.; Ran, Y.; Zhang, M.; Yang, B.; Lu, H.; Lin, S.; Zhang, L.; Zhou, F. MAVS deSUMOylation by SENP1 inhibits its aggregation and antagonizes IRF3 activation. Nat. Struct. Mol. Biol. 2023, 30, 785–799. [Google Scholar] [CrossRef]
- Hendriks, I.A.; D’Souza, R.C.J.; Yang, B.; Verlaan-De Vries, M.; Mann, M.; Vertegaal, A.C.O. Uncovering global SUMOylation signaling networks in a site-specific manner. Nat. Struct. Mol. Biol. 2014, 21, 927–936. [Google Scholar] [CrossRef] [PubMed]
- Sa Ribero, M.; Jouvenet, N.; Dreux, M.; Nisole, S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020, 16, e1008737. [Google Scholar] [CrossRef]
- Diamond, M.S.; Kanneganti, T.D. Innate immunity: The first line of defense against SARS-CoV-2. Nat. Immunol. 2022, 23, 165–176. [Google Scholar] [CrossRef]
- Hu, M.M.; Shu, H.B. Cytoplasmic Mechanisms of Recognition and Defense of Microbial Nucleic Acids. Annu. Rev. Cell Dev. Biol. 2018, 34, 357–379. [Google Scholar] [CrossRef]
- Li, S.; Kuang, M.; Chen, L.; Li, Y.; Liu, S.; Du, H.; Cao, L.; You, F. The mitochondrial protein ERAL1 suppresses RNA virus infection by facilitating RIG-I-like receptor signaling. Cell Rep. 2021, 34, 108631. [Google Scholar] [CrossRef] [PubMed]
- Lozhkov, A.A.; Plotnikova, M.A.; Egorova, M.A.; Baranovskaya, I.L.; Elpaeva, E.A.; Klotchenko, S.A.; Vasin, A.V. Simultaneous Detection of RIG-1, MDA5, and IFIT-1 Expression Is a Convenient Tool for Evaluation of the Interferon-Mediated Response. Viruses 2022, 14, 2090. [Google Scholar] [CrossRef]
- Wu, B.; Hur, S. How RIG-I like receptors activate MAVS. Curr. Opin. Virol. 2015, 12, 91–98. [Google Scholar] [CrossRef]
- Gori Savellini, G.; Anichini, G.; Gandolfo, C.; Cusi, M.G. SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity. Viruses 2021, 13, 1439. [Google Scholar] [CrossRef] [PubMed]
- Thoresen, D.; Wang, W.; Galls, D.; Guo, R.; Xu, L.; Pyle, A.M. The molecular mechanism of RIG-I activation and signaling. Immunol. Rev. 2021, 304, 154–168. [Google Scholar] [CrossRef]
- Song, B.; Chen, Y.; Liu, X.; Yuan, F.; Tan, E.Y.J.; Lei, Y.; Song, N.; Han, Y.; Pascal, B.D.; Griffin, P.R.; et al. Ordered assembly of the cytosolic RNA-sensing MDA5-MAVS signaling complex via binding to unanchored K63-linked poly-ubiquitin chains. Immunity 2021, 54, 2218–2230. [Google Scholar] [CrossRef] [PubMed]
- Sahin, U.; de Thé, H. Lallemand-Breitenbach V: Sumoylation in Physiology, Pathology and Therapy. Cells 2022, 11, 814. [Google Scholar] [CrossRef]
- Li, W.; Qiao, J.; You, Q.; Zong, S.; Peng, Q.; Liu, Y.; Hu, S.; Liu, W.; Li, S.; Shu, X.; et al. SARS-CoV-2 Nsp5 Activates NF-κB Pathway by Upregulating SUMOylation of MAVS. Front. Immunol. 2021, 12, 750969. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Huang, C.; Yin, Y.; Pan, P.; Huang, Y.; Chen, S.; Chen, J.; Wang, J.; Xu, G.; Tao, X.; Xiao, X.; et al. The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation. Viruses 2023, 15, 2304. https://doi.org/10.3390/v15122304
Huang C, Yin Y, Pan P, Huang Y, Chen S, Chen J, Wang J, Xu G, Tao X, Xiao X, et al. The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation. Viruses. 2023; 15(12):2304. https://doi.org/10.3390/v15122304
Chicago/Turabian StyleHuang, Congcong, Yiping Yin, Pan Pan, Yanping Huang, Siwei Chen, Junkai Chen, Ju Wang, Guoqing Xu, Xuan Tao, Xiao Xiao, and et al. 2023. "The Interaction between SARS-CoV-2 Nucleocapsid Protein and UBC9 Inhibits MAVS Ubiquitination by Enhancing Its SUMOylation" Viruses 15, no. 12: 2304. https://doi.org/10.3390/v15122304